2026 Pediatric Rheumatology Symposium

March 18-21, 2026. Minneapolis, MN.

View by Number View by Title View Sessions

Abstract Number: 092

Treatment-Refractory Juvenile Idiopathic Arthritis: Clinical Features and Biologic/Targeted Synthetic DMARD Utilization Patterns in a Single-Center Cohort
Abstract Number: 093

HOW DO WE HANDLE STILL’S DISEASE? REAL-LIFE CLINICIANS’ CHOICES FROM THE METAPHOR PROJECT WORLDWIDE SURVEY
Abstract Number: 094

Identification of Distinct Disease Trajectory Patterns in Children with Chronic Nonbacterial Osteomyelitis (CNO) Using Unsupervised Machine Learning on Longitudinal Clinical Data from a Single Cohort of 267 Patients
Abstract Number: 095

Rheum2Fake: Lessons from Severe Nutritional Deficiencies
Abstract Number: 096

Acute Care Utilization in New-Onset Childhood Systemic Lupus Erythematosus: Insights from a Pilot Study
Abstract Number: 097

Evaluating Associations between Diffusion Tensor Imaging Metrics and Cognitive Function in Youth with Childhood-Onset Systemic Lupus Erythematosus (cSLE)
Abstract Number: 098

Investigating S100 Proteins as Biomarkers for Pediatric Localized Scleroderma
Abstract Number: 099

Clinical Features of Juvenile Antisynthetase Syndrome: A Single-Center Case Series
Abstract Number: 100

Experience with Janus Kinase Inhibitors and Abatacept in Juvenile Dermatomyositis: A Retrospective Study from a Large Tertiary Center
Abstract Number: 101

Identifying Intervention Targets to Reduce Emotional Distress and Improve Physical Activity in Juvenile Lupus and Dermatomyositis Patients: Longitudinal Analysis of Lupus Erythematosus and Dermatomyositis Stress and Cardiovascular Health Study Patient-Reported Resiliency Data
Abstract Number: 102

Positive Affect and Emotion Regulation Protect Juvenile-Onset Lupus and Dermatomyositis Patients from Emotional Distress: Longitudinal Analysis of Lupus Erythematosus and Dermatomyositis Stress and Cardiovascular Health Cohort Study Parent-Reported Resiliency Data
Abstract Number: 103

Anifrolumab Use in Youngsters with Rheumatic Conditions: Case Series and a Review of the Evidence Base
Abstract Number: 104

Identification of Joints with Active Arthritis from Clinical Notes with High Fidelity using a Large Language Model
Abstract Number: 105

Rheumatological Biomarkers and Symptom Progression in Pediatric Systemic Lupus Erythematosus (SLE)
Abstract Number: 106

Clinical Characteristics and Safety Outcomes in Refractory Kawasaki Disease Treated with Second-Dose Infliximab

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].